Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second-line glucose-lowering therapy: The global DISCOVER study.

ABSTRACT:

Aims

To describe glucose-lowering treatment regimens and glycated haemoglobin (HbA1c) trajectories in individuals with type 2 diabetes (T2D) over 36 months of follow-up from the start of second-line therapy.

Materials and methods

This data analysis from the 3-year, observational DISCOVER study programme included 14 687 participants from 37 countries with T2D initiating second-line glucose-lowering therapy. Treatment and HbA1c data were collected at baseline (start of second-line therapy) and at 6, 12, 24 and 36 months. Treatment regimen changes over follow-up were analysed using the McNemar test, with carry-forward imputation for intermediate missing values.

Results

A total of 11 592 participants had treatment data at baseline and 36 months, and 11 882 had HbA1c data

SUBMITTER: Charbonnel BH 

PROVIDER: S-EPMC10087302 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature